Alembic Pharmaceuticals Limited has informed the Exchange about Copy of Newspaper Publication
APLLTD · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Alembic Pharmaceuticals has submitted to NSE copies of newspaper advertisements publishing its consolidated unaudited financial results for the quarter and half year ended 30 September 2025, as required under SEBI Listing Regulations. Consolidated total income from operations rose to ₹1,910.15 crore from ₹1,647.98 crore in the same quarter last year, a growth of about 16%. Net profit after tax grew to ₹184.71 crore (₹153.41 crore in Q2 FY25), while EPS stood at ₹9.40 versus ₹7.79 earlier. Standalone numbers also improved, with profit after tax at ₹179.36 crore compared to ₹165.78 crore. The results were published in Economic Times, Indian Express (English) and Financial Express (Gujarati) on 5 November 2025.
The filing itself is a routine disclosure, but the underlying results are positive, showing healthy double-digit growth in both revenue and profit on a YoY basis, which is mildly positive for shareholders and could support sentiment in the stock.